MYD88 and malignant colon neoplasm: IRF5 mediates growth inhibition by arresting G2-M cell cycle [27], sensitizes p53-proficient and p53-deficient colon cancer cells to DNA damage-induced apoptosis [28], and mediates inflammatory and immune responses by controlling expression of pro-inflammatory cytokines downstream of MyD88-dependent TLR signaling [32].